Publications by authors named "Yu-Tzu Tai"

100Publications

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

Leukemia 2020 Jul 6. Epub 2020 Jul 6.

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0951-5DOI Listing
July 2020

Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.

Clin Lymphoma Myeloma Leuk 2020 May 27. Epub 2020 May 27.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.014DOI Listing
May 2020

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.

Cancers (Basel) 2020 Jun 5;12(6). Epub 2020 Jun 5.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352710PMC
June 2020

IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.

Eur J Haematol 2020 Sep 9;105(3):326-334. Epub 2020 Jun 9.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13440DOI Listing
September 2020

Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.

Mol Cancer Res 2020 Jul 20;18(7):1063-1073. Epub 2020 Apr 20.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-19-0852DOI Listing
July 2020

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

Leukemia 2020 Aug 14;34(8):2150-2162. Epub 2020 Feb 14.

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0745-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392808PMC
August 2020

The impact of response kinetics for multiple myeloma in the era of novel agents.

Blood Adv 2019 10;3(19):2895-2904

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019000432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784522PMC
October 2019

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.

Leukemia 2020 02 7;34(2):578-588. Epub 2019 Oct 7.

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0590-xDOI Listing
February 2020

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.

Leukemia 2020 02 28;34(2):567-577. Epub 2019 Aug 28.

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0558-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132142PMC
February 2020

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Expert Opin Biol Ther 2019 11 11;19(11):1143-1156. Epub 2019 Jul 11.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1641196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785394PMC
November 2019

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Ann Transl Med 2018 Dec;6(Suppl 2):S93

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.11.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330615PMC
December 2018

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Front Immunol 2018 10;9:1822. Epub 2018 Aug 10.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095980PMC
September 2019

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Front Immunol 2018 10;9:1821. Epub 2018 Aug 10.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, United States.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.01821
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.01821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095983PMC
September 2019

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Leukemia 2019 02 22;33(2):426-438. Epub 2018 Aug 22.

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0242-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367000PMC
February 2019

Widespread intronic polyadenylation diversifies immune cell transcriptomes.

Nat Commun 2018 04 30;9(1):1716. Epub 2018 Apr 30.

Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-04112-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928244PMC
April 2018

Targeting CD38 alleviates tumor-induced immunosuppression.

Oncotarget 2017 Dec 26;8(68):112166-112167. Epub 2017 Dec 26.

The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22992DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762499PMC
December 2017

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Antibodies (Basel) 2017 Nov 14;6(4). Epub 2017 Nov 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/antib6040018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698817PMC
November 2017

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.

Exp Hematol Oncol 2017 14;6:20. Epub 2017 Jul 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-017-0081-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512936PMC
July 2017

MUC1-C is a target in lenalidomide resistant multiple myeloma.

Br J Haematol 2017 09 23;178(6):914-926. Epub 2017 Jun 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591051PMC
September 2017

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Clin Cancer Res 2017 Sep 25;23(17):5225-5237. Epub 2017 Apr 25.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581671PMC
September 2017

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Clin Cancer Res 2017 Aug 1;23(15):4290-4300. Epub 2017 Mar 1.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-3192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540790PMC
August 2017

A new era of immune therapy in multiple myeloma.

Blood 2016 07;128(3):318-9

DANA-FARBER CANCER INSTITUTE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-06-719856DOI Listing
July 2016

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Blood 2016 09 14;128(12):1590-603. Epub 2016 Jul 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-03-707547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034739PMC
September 2016

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.

Blood 2016 07 18;128(2):249-52. Epub 2016 May 18.

Medical Oncology, and LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; VA Boston Healthcare System, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-03-704460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946203PMC
July 2016

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Blood 2016 06 28;127(25):3225-36. Epub 2016 Apr 28.

The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-01-691162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920023PMC
June 2016

Targeting B-cell maturation antigen in multiple myeloma.

Immunotherapy 2015 15;7(11):1187-99. Epub 2015 Sep 15.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.15.77DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976846PMC
September 2016

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

Cancer Discov 2015 Sep 16;5(9):972-87. Epub 2015 Jun 16.

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560623PMC
September 2015

The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.

Clin Cancer Res 2015 May 4;21(9):2148-56. Epub 2015 Feb 4.

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2576DOI Listing
May 2015

Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.

Exp Hematol 2015 Mar 20;43(3):168-176.e2. Epub 2014 Nov 20.

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2014.11.004DOI Listing
March 2015

Differential and limited expression of mutant alleles in multiple myeloma.

Blood 2014 Nov 18;124(20):3110-7. Epub 2014 Sep 18.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Hematology/Oncology, Boston Veterans Administration Healthcare System, West Roxbury, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-04-569327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231420PMC
November 2014

Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.

Ann Hematol 2015 Feb 18;94(2):257-64. Epub 2014 Sep 18.

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00277-014-2211
Web Search
http://link.springer.com/10.1007/s00277-014-2211-0
Publisher Site
http://dx.doi.org/10.1007/s00277-014-2211-0DOI Listing
February 2015

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.

Cancer Res 2014 Mar 5;74(6):1801-13. Epub 2014 Mar 5.

Authors' Affiliations: Department of Medical Oncology; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Department of Pathology, Brigham & Women's Hospital; Department of Developmental Biology, Harvard School of Dental Medicine; Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center, Boston, Massachusetts; and Experimental Therapies, H. Lee Moffitt Cancer Center, Florida; and Department of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai, China.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-13-3311-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959627PMC
March 2014

Daratumumab granted breakthrough drug status.

Expert Opin Investig Drugs 2014 Apr 20;23(4):445-52. Epub 2014 Feb 20.

Medical Oncologist, Dana-Farber Cancer Institute, Harvard Medical School, Je Lipper Multiple Myeloma Center , 450 Brookline Ave., Mayer 556, Boston, MA 02215 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2014.889681DOI Listing
April 2014

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Blood 2014 Jan 6;123(5):706-16. Epub 2013 Dec 6.

Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-05-500033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907756PMC
January 2014

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Blood 2013 Aug 3;122(7):1243-55. Epub 2013 Jul 3.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-02-483511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744991PMC
August 2013

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.

Blood 2012 Nov 14;120(19):3958-67. Epub 2012 Sep 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-01-40
Publisher Site
http://dx.doi.org/10.1182/blood-2012-01-401794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496955PMC
November 2012

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Br J Haematol 2012 Jun 26;157(6):718-31. Epub 2012 Apr 26.

Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2012.09120.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414398PMC
June 2012

Antibody-based therapies in multiple myeloma.

Bone Marrow Res 2011 2;2011:924058. Epub 2011 Mar 2.

Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2011/924058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200112PMC
November 2011

Aneurysm bone cyst presented as a zygomatic mass after facial trauma.

J Trauma 2011 Apr;70(4):E74

Department of Dermatology, Chung-Shan Medical University Hospital, Taichung City, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TA.0b013e3181a5a791DOI Listing
April 2011

Frontal contusion epidural hematoma that mimics a tensioned retrobulbar hemorrhage in clinical presentation.

J Trauma 2010 Jul;69(1):239

Department of Surgery, Division of Plastic Surgery, China Medical University Hospital, Taichung City, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TA.0b013e3181647c81DOI Listing
July 2010